

# A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

NCT07310901

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Corbus Pharmaceuticals Inc.
Enrollment	252 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Part 1: Participants with BMI 18.0-25.0 kg/m<sup>2</sup>
- Part 2: Obese participants with BMI  $\geq$ 30 kg/m<sup>2</sup>

### Exclusion (20)

- Significant liver disease or moderate-severe hepatic impairment
- History of seizures, epilepsy, or intracranial surgery
- Diabetes mellitus (Type 1 or Type 2), except gestational
- Bariatric surgery or  $\geq$ 5 kg weight change in past 3 months
- Recent use (within 3 months) of GLP-1 agonists or other weight-loss medications
- ... and 15 more (see full listing online)

## Locations (15 total)

---

Central Alabama Research, Birmingham, Alabama, United States  
Arizona Clinical Trials, Chandler, Arizona, United States  
Prospective Research Innovations, Rancho Cucamonga, California, United States  
... and 12 more locations